Background and Objectives: The prognostic significance of dynamic changes in glomerular filtration rate (GFR) during targeted therapies in metastatic renal cell carcinoma (mRCC) is not well understood. Thus, we aimed to investigate the prognostic significance of GFR value at 6 months in patients with mRCC receiving first-line targeted therapy. Materials and Methods: This retrospective cohort study included 260 mRCC patients at two tertiary centers in Turkey between 2015 and 2025. Patients were stratified into three groups according to GFR at 6 months: ≥60, 30–60, and <30 mL/min/1.73 m². Kaplan–Meier curves were used to estimate progression-free survival (PFS) and overall survival (OS) in prognostic subgroups. Cox proportional hazard models assessed associations between clinicopathologic variables, including GFR categories, and PFS and OS. Results: The median PFS for the cohort was 11.1 months (95% confidence interval [CI]: 9.3–12.9), and the median OS was 40.0 months (95% CI: 30.3–49.7). In multivariate analysis, GFR < 30 mL/min/1.73 m² was independently associated with shorter PFS (hazard ratio [HR]: 1.54, 95% CI: 1.01–2.33, p = 0.040) and OS (HR: 3.80, 95% CI: 2.06–7.01, p < 0.001), while GFR 30–60 mL/min/1.73 m² was linked to reduced OS (HR: 2.07, 95% CI: 1.08–3.98, p = 0.028). Additional independent predictors of worsened PFS were intermediate (p = 0.028) and poor IMDC risk (p < 0.001. For OS, liver metastases (p = 0.017), bone metastases (p = 0.014), brain metastases (p = 0.002), and intermediate (p = 0.014) or poor IMDC risk (p < 0.001) were also significant. Conclusions: In patients with mRCC treated with targeted therapy, the GFR at 6 months is an independent factor in predicting survival outcomes, indicating the clinical significance of serial kidney function monitoring.

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Although the STRIDE regimen (durvalumab plus tremelimumab) has demonstrated an overall survival benefit in clinical trials, real-world evidence remains limited, particularly in Turkish clinical practice. This study aimed to evaluate the effectiveness and safety of first-line STRIDE therapy in patients with unresectable HCC treated in routine clinical practice. Methods: We conducted a retrospective multicenter study including patients with unresectable HCC who received first-line durvalumab plus tremelimumab through the Turkish national Early Access Program across 18 oncology centers. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory Cox regression analyses were performed to evaluate baseline prognostic factors. Results: Thirty-two patients were included. The median PFS was 7.25 months (95% CI, 3.68–22.29), and the median OS was 11.43 months (95% CI, 4.50–not reached). The underlying liver disease etiology was non-viral in 53.1% of patients, hepatitis B virus in 40.6%, and hepatitis C virus in 6.3%. Grade ≥ 3 treatment-related adverse events occurred in fewer than 10% of patients. Conclusions: In this multicenter real-world cohort, first-line durvalumab plus tremelimumab appeared to be a feasible treatment option and was generally well tolerated in patients with unresectable HCC. However, given the retrospective design, small sample size, and absence of a control group, these findings should be interpreted cautiously and require confirmation in larger prospective comparative studies.

Backround:Hepatocellular carcinoma (HCC) is the most common neoplasm to cause death. First line treatment options are still challenging for HCC. STRIDE regimen (durvalumab/tremelimumab) showed improved median overall survival (OS) rates however did not make differ significantly in median progression-free survival (PFS) rate. Method:We reviewed outcomes of patients with HCC who initiated durval-umab/tremelimumab between 2020 and 2024, across 18 institutions. OS and PFS were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteris-tics. Results: A total of 32 patients were included in the study. Median PFS was was 7,25 months (%95 confidence interval (CI) 3,68-22,29) and the median OS was 11,43 months (%95 CI 4,5-NA). Non-viral, HBV and HCV constituted to etiology was re-spectively %53,1, %40,6 and %6,3 of patients. Grade ≥ 3 advers events were found less than %10 of populations. Conclusions: This real world retrospective study showed that STRIDE regimen was effective and safety for HCC in first line.